Global Dry Powder Inhalers (DPIs) Market - 2025 - 2033

Global Dry Powder Inhalers (DPIs) Market - 2025 - 2033

The global dry powder inhalers market reached US$ 1.02 billion in 2024 and is expected to reach US$ 1.56 billion by 2033, growing at a CAGR of 5.1% during the forecast period 2025-2033.

Dry powder inhalers (DPIs) are medical devices that administer powdered drugs directly into the lungs. They are generally used to treat respiratory disorders like asthma and chronic obstructive pulmonary disease (COPD). A dry powder inhaler is distinguished by its breath-activated mechanism, which ensures that the drug is only released when the patient inhales deeply and forcefully via the mouthpiece. Unlike metered-dose inhalers (MDIs), which utilize propellants to administer medication, DPIs employ the patient's inhalation to disperse the powdered medication into an aerosol form that can reach the narrow airways of the lungs.

The increasing demand for dry powder inhalers is the driving factor that drives the market over the forecast period. For instance, the increasing prevalence of respiratory diseases increases the demand for dry powder inhalers since they play a vital role in the treatment and management of chronic respiratory diseases. For instance, according to the Asthma and Allergy Foundation of America, Nearly 28 million people in the United States suffer from asthma. This equates to around one in every twelve people. Asthma affects almost 23 million persons in the United States, aged 18 and older. Asthma is more frequent in women than men. Asthma affects around 11.0% of female adults and 6.8% of male people. It is a major chronic disease among youngsters. Currently, around 4.9 million children under the age of 18 have asthma.

Market Dynamics: Drivers & Restraints

Increasing demand for dry powder inhalers

The increasing demand for dry powder inhalers is expected to be a significant factor in the growth of the global dry powder inhalers market. The increasing number of cases of respiratory disorders, ease of drug delivery than traditional inhalers, technological advancements, increased research funds, and increasing awareness increase the demand for dry powder inhalers and drive the market.

As chronic respiratory conditions like COPD, asthma, and sinusitis become more prevalent globally, the demand for dry powder inhalers increases as it plays an important role in the management and control of chronic respiratory diseases like bronchitis, COPD, and asthma. For instance, according to the Department of Health & Human Services, 1 in 20 people globally suffers from chronic respiratory disease (CRD). East Asia and South Asia had the highest rates of CRD mortality. Low-middle and low Socio-demographic Index (SDI) countries had the highest age-standardized rates of CRD deaths. New findings on chronic respiratory disease (CRD) now show it is the third leading cause of death globally, accounting for approximately 4 million deaths worldwide. Asthma was diagnosed in approximately 60% of these people (approximately 262 million), making it the most common CRD. Since 1990, the number of new cases of CRDs has increased by 49.0%, owing primarily to population growth. The age-standardized incidence rate, on the other hand, has decreased by 5.3%.

The ease of drug delivery and user-friendly nature of dry powder inhalers to traditional inhalers increase the demand. One of the primary advantages of DPIs over typical inhalation devices is their ability to deliver medication directly to the lungs, eliminating the need for propellants or liquids. This attribute not only improves patient compliance but also reduces environmental effects. DPIs are intended to be user-friendly and portable, making them a suitable option for patients who require ongoing treatment for chronic respiratory disorders. The ease and effectiveness of DPIs are projected to drive their acceptance among both healthcare professionals and patients.

Furthermore, technological advancements in DPI design and formulation are driving market expansion. Innovations like capsule-based devices that decrease moisture exposure improve dependability and performance, resulting in higher patient satisfaction and adherence. The incorporation of smart technology into inhalers, such as sensors that monitor usage, creates new prospects for improving treatment outcomes and patient participation. These advancements not only meet existing patient needs but also attract new users who may have previously been unwilling to adopt inhalation therapy.

The funding allocated for the development and improvement of dry powder inhalers (DPIs) is critical to enhancing respiratory care and increasing access to effective therapies. For instance, in October 2023, The US Food and Drug Administration (FDA) funded Australian researchers $AU1 million ($US687,000) to develop improved dry powder inhaler testing procedures. The initiative will enable more effective development of inhalers, particularly generic inhaler devices, with the goal of providing access to affordable inhalers for asthma patients across the globe.

Side effects associated with the usage of dry powder inhalers

Factors such as side effects associated with the usage of dry powder inhalers are expected to hamper the global dry powder inhalers market. One major issue is the prevalence of oral thrush, a fungal disease that can develop when powdered drugs settle in the mouth or throat. According to research, using inhaled corticosteroids via DPIs increases the incidence of oral thrush, especially at larger doses. Patients may endure symptoms such as discomfort in the mouth, throat irritation, and hoarseness, which can influence their willingness to continue using these devices. Furthermore, some people may be sensitive to lactose, a frequent carrier found in many DPIs, which can cause gastrointestinal discomfort or allergic responses in lactose-intolerant patients.

In addition to local side effects, there are concerns regarding systemic side effects from continuous corticosteroid administration via DPIs. High doses over time might result in problems such as osteoporosis, diabetes, and other systemic disorders. These potential health hazards can increase patient anxiety over long-term DPI use and lead to nonadherence to prescribed therapy.

Segment Analysis

The global dry powder inhalers market is segmented based on product type, dosage, indication type, distribution channel, and region.

The multi-dose dry powder inhalers segment is anticipated to dominate the global dry powder inhalers market owing to its cost-effectiveness, longer shelf life, ease of use, strategic partnerships, and increasing prevalence of respiratory disorders.

One of the primary benefits of MDPIs is their cost-effectiveness. These devices often have a longer shelf life and less pharmaceutical waste, making them cost-effective for both patients and healthcare systems. The combination of price and ease of use makes MDPIs a popular alternative, particularly as healthcare providers prioritize effective and efficient respiratory disease treatment solutions.

Technological developments will also play an important part in the expansion of the multi-dose segment. Smart inhalers, which combine digital health solutions, improve patient involvement and treatment adherence. These devices can monitor usage patterns, remind patients to take their prescriptions and provide feedback on inhaling practices, ultimately enhancing treatment outcomes. As healthcare systems increasingly adopt digital health technology, MDPIs are likely to gain from greater integration into patient care initiatives.

For instance, according to the American Lung Association, COPD affects 11.7 million adults, resulting in hundreds of thousands of emergency department visits and tens of billions of dollars in healthcare expenses each year. Moreover, according to the Cystic Fibrosis Foundation, Cystic fibrosis affects about 40,000 children and adults in the United States (an estimated 105,000 people have been diagnosed with the disease in 94 countries), and it can affect people of any ethnic background. So, multi-dose dry powder inhalers play an important role in the treatment and management of chronic respiratory disorders. The increasing number of chronic respiratory disorders upsurges the demand for multi-dose dry powder inhalers.

The strategic partnerships took place to enhance the quality and efficiency of the multi-dose dry powder inhalers. For instance, in May 2023, H&T Presspart, a global supplier of drug delivery devices and components, announced a collaborative partnership with Hovione, a specialist integrated CDMO and leader in spray drying and particle engineering, to develop the new Sunrise high-performance dry powder inhaler technology platform. H&T Presspart's revolutionary Sunriser technology is adaptable enough to meet the challenges of both traditional carrier-based and spray-dried tailored formulations, as well as an expanding range of dry powder formulations, new particle engineering, and powder processing technologies. As part of the collaborative development agreement, H&T Presspart will continue to develop and manufacture the Sunriser device.

Geographical Analysis

The dominance of the North American market in the global dry powder inhaler market is due to various factors such as advanced healthcare infrastructure, high prevalence of respiratory diseases, strategic partnerships, technological advancements, product launches, and approvals, and increasing adoption of innovative medical technologies.

One of the primary factors contributing to North America's dominance in the dry powder inhaler market is technological improvements that improve the functionality and user experience of dry powder inhalers. Recent advances have focused on enhancing device usability, drug delivery accuracy, and patient adherence. Many recent DPI advancements include integrated dose counters and audible feedback mechanisms that assist patients in receiving the exact dosage while also serving as medication adherence reminders. Furthermore, advances in materials and design have resulted in the creation of lightweight, portable inhalers that are easier for patients to transport and use on the go.

For instance, in February 2024, Catalent, Inc., a global leader in enabling the development and supply of better therapies for patients, completed remodeling and device advancement to its capsule filling of Dry Powders for Inhalation and capsule blistering suites in Boston, MA, to handle strong pharmaceuticals. Catalent is currently the CDMO with the most GMP capacity for capsule spray-dried and carrier-based inhaled powders, due to recent enhancements that include more capacity for both development and commercial spray drying.

The increasing prevalence of respiratory disorders in this region increases the demand for dry powder inhalers. For instance, according to health.gov, respiratory diseases affect millions of people in the United States. More than 25 million people in the United States have asthma. Strategies to reduce environmental triggers and make sure people get the right medications can help prevent hospital visits for asthma. In addition, more than 16 million people in the United States have COPD (chronic obstructive pulmonary disease), which is a major cause of death.

Asia Pacific is growing at the fastest pace in the global dry powder inhalers market

The Asia Pacific region is emerging as the fastest-growing market for dry powder inhalers, owing to a combination of demographic trends, increased healthcare investment, recent launches, and an increasing prevalence of respiratory diseases.

The increasing prevalence of respiratory diseases is one of the factors that drive the market in this region. For instance, according to The International Primary Care Respiratory Group, India has one of the highest rates of chronic respiratory illness. India accounts for 15.69% of worldwide chronic respiratory diseases, whereas 30.28% of all global deaths from chronic respiratory diseases occur in India. India has the world's greatest number of COPD (Chronic Obstructive Pulmonary Disease) cases, totaling 55.23 million. India has the second-highest number of COPD-related deaths globally, accounting for almost 0.85 million.

There are recent product launches of anesthesia devices in this region. For instance, in 2023, Aptar Pharma launched Orbital Dry Powder Inhaler (DPI), a revolutionary device for delivering high-payload powder medication formulations directly to the lungs. This innovative inhaler technology stands out for its ability to give accurate and consistent dosing over several inhalations, which improves patient compliance and minimizes the risk of coughing during administration. The Orbital DPI is adaptable to both single-use and reuse applications, making it suitable for a wide range of therapeutic purposes.

Competitive Landscape

The major global players in the global dry powder inhalers market include AstraZeneca, Boehringer Ingelheim International GmbH, Vectura Group Ltd, Otsuka Pharmaceutical Co., Ltd., Respira Therapeutics Inc., CHIESI Farmaceutici S.p.A., Cipla, GlaxoSmithKline plc., Hovione, Mankind Pharma among others.

Emerging Players

Merxin Ltd, Aerovate Therapeutics, and PULMATRiX, Inc. among others

Key Developments
• In November 2024, Aptar Pharma, a global leader in drug delivery and active material science solutions and services, announced that it has signed an exclusive collaboration agreement with Cambridge Healthcare Innovations (CHI) to commercialize and promote its Quattrii Dry Powder Inhaler (DPI) platform.
• In April 2024, Berry Global, a leader in the design, development, and manufacturing of patient-centered healthcare solutions, recently introduced the BerryHaler, a dual chamber, dry powder inhaler (DPI) with a dose counter that improves patient access to and supports the effective delivery of combination drugs.

Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global dry powder inhalers market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.